Literature DB >> 1687369

Effects of porcine relaxin on contraction, membrane response and cyclic AMP content in rat myometrium in comparison with the effects of isoprenaline and forskolin.

T Osa1, H Inoue, K Okabe.   

Abstract

1. The longitudinal muscle from the uterus of oestrogen-treated rats was quiescent in Mg-free Krebs solution. Electrical stimulation generated phasic contraction, which was depressed to 35% and 18% by 50 mu and 150 mu porcine relaxin, respectively. 2. The phasic contractions were more strongly depressed to 26% by 50 mu relaxin in solution containing 0.6 mM Mg, and the depression lasted for more than 4 h after the removal of relaxin. During the persisting depression, raising the external Ca to 7.5 mM did not restore the contraction, but the contraction was restored by removal of Mg. 3. The depression of the phasic contraction by relaxin, examined in Mg-free solution, was enhanced and reduced by pretreatment of the tissue with 0.6 mM Mg and 0.6 mM Mn, respectively, for about 15 min. In contrast, the depression of contraction by isoprenaline or forskolin was enhanced by pretreatment with either Mg or Mn. 4. The cellular content of cyclic AMP was measured in Krebs solution containing 0.6 mM Mg. The values were 1.24 (pmol mg-1 protein) in control solution, and 2.31 and 1.56 when the tissues were treated with 150 mu relaxin and 10(-9) M isoprenaline, respectively. 5. The cyclic AMP production in response to 10(-7) M forskolin measured in Mg-free solution was enhanced when the tissue was pretreated with either 0.6 mM Mg or Mn for 15 min. The cyclic AMP production in response to 100 mu relaxin was increased when the tissue was pretreated with 0.6 mM Mg, and was unchanged by pretreatment with Mn. The cyclic AMP production in response to 10(-9) M isoprenaline was unchanged by pretreatment with the divalent cations. 6. The membrane potential of the muscle was -60.8 mV in Krebs solution containing 0.3 mM Mg, and electrical stimulation induced an action potential which consisted of spike and plateau components. Application of 150 mu relaxin reduced the duration of the plateau; the contractions were progressively depressed. The resting membrane potential and membrane resistance were unchanged by application of 150 mu relaxin. The membrane was hyperpolarized by 2.8 mV, accompanied by a decrease in membrane resistance, when 10(-9) M isoprenaline was applied. 7. Although there were several differences between the effects of relaxin and isoprenaline, it is probable that some process, which is cyclic AMP-dependent, accelerated by Mg and depressed by Mn, is involved in the depressant action of relaxin on contraction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687369      PMCID: PMC1908840          DOI: 10.1111/j.1476-5381.1991.tb12532.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Inhibition of the spontaneous uterine motility in vitro as a bioassay of relaxin.

Authors:  N WIQVIST; K G PAUL
Journal:  Acta Endocrinol (Copenh)       Date:  1958-09

2.  Relaxin receptor in the rat myometrium: regulation by estrogen and relaxin.

Authors:  R C Mercado-Simmen; G D Bryant-Greenwood; F C Greenwood
Journal:  Endocrinology       Date:  1982-01       Impact factor: 4.736

Review 3.  Adenylate cyclase: the role of magnesium and other divalent cations.

Authors:  S Y Cech; W C Broaddus; M E Maguire
Journal:  Mol Cell Biochem       Date:  1980-12-10       Impact factor: 3.396

4.  The relationship between calmodulin binding and phosphorylation of smooth muscle myosin kinase by the catalytic subunit of 3':5' cAMP-dependent protein kinase.

Authors:  M A Conti; R S Adelstein
Journal:  J Biol Chem       Date:  1981-04-10       Impact factor: 5.157

Review 5.  Relaxin.

Authors:  G Weiss
Journal:  Annu Rev Physiol       Date:  1984       Impact factor: 19.318

Review 6.  Regulation and kinetics of the actin-myosin-ATP interaction.

Authors:  R S Adelstein; E Eisenberg
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

7.  Characterization of the binding of 125I-relaxin to rat uterus.

Authors:  R C Mercado-Simmen; G D Bryant-Greenwood; F C Greenwood
Journal:  J Biol Chem       Date:  1980-04-25       Impact factor: 5.157

8.  Effects of relaxin on rat uterine myosin light chain kinase activity and myosin light chain phosphorylation.

Authors:  K Nishikori; N W Weisbrodt; O D Sherwood; B M Sanborn
Journal:  J Biol Chem       Date:  1983-02-25       Impact factor: 5.157

9.  Purification and characterization of myosin light-chain kinase from porcine myometrium and its phosphorylation and modulation by cyclic AMP-dependent protein kinase.

Authors:  K Higashi; K Fukunaga; K Matsui; M Maeyama; E Miyamoto
Journal:  Biochim Biophys Acta       Date:  1983-09-28

10.  Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells.

Authors:  K B Seamon; W Padgett; J W Daly
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

View more
  4 in total

Review 1.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

3.  Cellular localization of the inhibitory action of relaxin against uterine spasm.

Authors:  S J Hughes; M Hollingsworth
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

4.  The lack of a role for potassium channel opening in the action of relaxin in the rat isolated uterus; a comparison with levcromakalim and salbutamol.

Authors:  S J Hughes; M Hollingsworth
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.